Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NU6Y
|
|||
| Former ID |
DIB006221
|
|||
| Drug Name |
192C86
|
|||
| Synonyms |
BW-192C86
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 1 | [1] | |
| Company |
Burroughs Wellcome Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H33N3O4S
|
|||
| Canonical SMILES |
CCN1C2CC(CC2N(C1=O)N=CC(C3CCCCC3)O)SCCCC(=O)O
|
|||
| InChI |
1S/C20H33N3O4S/c1-2-22-16-11-15(28-10-6-9-19(25)26)12-17(16)23(20(22)27)21-13-18(24)14-7-4-3-5-8-14/h13-18,24H,2-12H2,1H3,(H,25,26)/b21-13+
|
|||
| InChIKey |
YDMMNNOYPGHBEY-FYJGNVAPSA-N
|
|||
| CAS Number |
CAS 139147-26-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor (PTGDR) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathwhiz Pathway | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | |||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The effect of a prostaglandin DP-receptor partial agonist (192C86) on platelet aggregation and the cardiovascular system in healthy volunteers. Br J Clin Pharmacol. 1992 Oct;34(4):344-51. | |||
| REF 2 | Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.